EyeGate Pharmaceuticals Inc. EyeGate Pharma Reaches 75 Randomization of Patients in Pivotal Study

EyeGate Pharmaceuticals, Inc.: EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study

06:56 EDT 16 Sep 2019 | FinanzNachrichten

WALTHAM, MA / ACCESSWIRE / September 16, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disord...

More From BioPortfolio on "EyeGate Pharmaceuticals, Inc.: EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study"